- Home
- MNPR vs OPP Comparison
MNPR vs OPP Comparison
Compare MNPR & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- OPP
- Stock Information
- Founded
- MNPR 2014
- OPP 2010
- Country
- MNPR United States
- OPP United States
- Employees
- MNPR N/A
- OPP N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- OPP Finance/Investors Services
- Sector
- MNPR Health Care
- OPP Finance
- Exchange
- MNPR Nasdaq
- OPP Nasdaq
- Market Cap
- MNPR 209.3M
- OPP 199.8M
- IPO Year
- MNPR 2019
- OPP N/A
- Fundamental
- Price
- MNPR $44.97
- OPP $8.50
- Analyst Decision
- MNPR Strong Buy
- OPP
- Analyst Count
- MNPR 7
- OPP 0
- Target Price
- MNPR $62.00
- OPP N/A
- AVG Volume (30 Days)
- MNPR 69.5K
- OPP 108.0K
- Earning Date
- MNPR 08-08-2025
- OPP 01-01-0001
- Dividend Yield
- MNPR N/A
- OPP 14.41%
- EPS Growth
- MNPR N/A
- OPP N/A
- EPS
- MNPR N/A
- OPP N/A
- Revenue
- MNPR N/A
- OPP N/A
- Revenue This Year
- MNPR N/A
- OPP N/A
- Revenue Next Year
- MNPR N/A
- OPP N/A
- P/E Ratio
- MNPR N/A
- OPP N/A
- Revenue Growth
- MNPR N/A
- OPP N/A
- 52 Week Low
- MNPR $1.72
- OPP $7.26
- 52 Week High
- MNPR $54.30
- OPP $8.83
- Technical
- Relative Strength Index (RSI)
- MNPR 59.21
- OPP 55.15
- Support Level
- MNPR $44.26
- OPP $8.45
- Resistance Level
- MNPR $47.52
- OPP $8.48
- Average True Range (ATR)
- MNPR 3.49
- OPP 0.07
- MACD
- MNPR 0.54
- OPP -0.00
- Stochastic Oscillator
- MNPR 64.49
- OPP 62.16
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.